Chong Kun Dang bought the domestic license for MSD’s blockbuster diabetes treatment ‘Januvia series’. It is equipped with a stable cash cow that raises more than 100 billion won a year. Chong Kun Dang signed a license agreement with MSD headquarters in Switzerland to introduce all domestic rights for three diabetes treatments, Januvia, Janumet, and Janumet XR. Chong Kun Dang acquires not only domestic sales and distribution rights for the three Januvia series, but also all rights such as licenses, trademarks, and manufacturing. The contract period is from July 15th to August 31st, 2038. The total contract amount is 45.5 billion won. Chong Kun Dang paid MSD headquarters a down payment of 23 billion won, and the milesto